This week, industry, research institutions, investors and advocacy organizations will gather in Boston, May 17-19, for Informa’s Rare Disease Innovation & Partnering Summit. It’s a pivotal time for rare disease – with policy and market forces combining to present potential threats to innovation, and with new and emerging partnering models offering promise for increased R&D productivity and commercialization of rare disease therapies.
Global Genes will be kicking off the summit (and a new initiative called REDI (RARE Entrepreneurial Development & Incubation), designed to address some of the challenges described above) with a networking reception May 16, from 6-8pm ET at the rooftop bar of the Revere Hotel Boston Common, where the summit is being held. You do not have to be registered for the Partnering Summit to attend this reception.
During the summit, Craig Martin, Global Genes CEO, will also be participating in several sessions, including:
Cutting Through the Headwinds – Advancing New Models to Enable Rare Disease Innovation to Continue to Thrive (presentation)
May 17, 12pm
Fellow participants in this session include Rodney Samaco, Assistant Professor and Investigator, Baylor College of Medicine; Walt Kowtoniuk, Venture Partner, Third Rock Ventures, Casey McPherson, Founder & President of To Cure A Rose Foundation, and Giacomo Chiesi, Global Head of Rare Diseases for the Chiesi Group.
Optimize Strategic Partnership Models and Investment for Orphan Drug Products (Workshop)
May 17, 4:30pm
Craig and Imran Babar, Chief Business Officer at Cydan, will explore strategic partnership models and valuation considerations in drug development ventures.
Identify Gaps and Develop Solutions to Promote Diversity, Equity and Inclusion (Panel Discussion)
May 18, 12pm
Tammy Boyd, MPH, JD, Chief Policy Officer & Senior Counsel, Black Women’s Health Imperative will join Craig to discuss the disparities in the rare disease world, including clinical trials, advocacy, and solutions for accessible care.